Dr. Yoshino, chairman of 22CEMIT, became the first Japanese to give a presentation at the Plenary Session of ASCO2022!
Takayuki Yoshino, chairman of 22CEMIT, presented a paper entitled
"Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial."
at the Plenary Session (Abstract #LBA1) of American Society of Clinical Oncology (ASCO2022) held in Chicago.
We are proud to announce that he is the first Japanese to present at the ASCO Plenary Session!
To see ASCO2022 website regarding the presentation, Click here
Back to top
Recommend
English 
Japanese